PURPOSE: We assessed risk factors for end stage renal disease in patients with Wilms tumor without known WT1 related syndromes. We hypothesized that patients with characteristics suggestive of a WT1 etiology (early onset, stromal predominant histology, intralobar nephrogenic rests) would have a higher risk of end stage renal disease due to chronic renal failure. We predicted a high risk of end stage renal disease due to progressive bilateral Wilms tumor in patients with metachronous bilateral disease. MATERIALS AND METHODS: End stage renal disease was ascertained in 100 of 7,950 nonsyndromic patients enrolled in a National Wilms Tumor Study during 1969 to 2002. Risk factors were evaluated with cumulative incidence curves and proportional hazard regressions. RESULTS: The cumulative incidence of end stage renal disease due to chronic renal failure 20 years after Wilms tumor diagnosis was 0.7%. For end stage renal disease due to progressive bilateral Wilms tumor the incidence was 4.0% at 3 years after diagnosis in patients with synchronous bilateral Wilms tumor and 19.3% in those with metachronous bilateral Wilms tumor. For end stage renal disease due to chronic renal failure stromal predominant histology had a HR of 6.4 relative to mixed (95% CI 3.4, 11.9; p<0.001), intralobar rests had a HR of 5.9 relative to no rests (95% CI 2.0, 17.3; p=0.001), and Wilms tumor diagnosis at less than 24 months had a HR of 1.7 relative to 24 to 48 months and 2.8 relative to greater than 48 months (p=0.003 for trend). CONCLUSIONS: Metachronous bilateral Wilms tumor is associated with high rates of end stage renal disease due to surgery for progressive Wilms tumor. Characteristics associated with a WT1 etiology markedly increased the risk of end stage renal disease due to chronic renal failure despite the low risk in non-WT1 syndromic cases overall.
PURPOSE: We assessed risk factors for end stage renal disease in patients with Wilms tumor without known WT1 related syndromes. We hypothesized that patients with characteristics suggestive of a WT1 etiology (early onset, stromal predominant histology, intralobar nephrogenic rests) would have a higher risk of end stage renal disease due to chronic renal failure. We predicted a high risk of end stage renal disease due to progressive bilateral Wilms tumor in patients with metachronous bilateral disease. MATERIALS AND METHODS:End stage renal disease was ascertained in 100 of 7,950 nonsyndromic patients enrolled in a National Wilms Tumor Study during 1969 to 2002. Risk factors were evaluated with cumulative incidence curves and proportional hazard regressions. RESULTS: The cumulative incidence of end stage renal disease due to chronic renal failure 20 years after Wilms tumor diagnosis was 0.7%. For end stage renal disease due to progressive bilateral Wilms tumor the incidence was 4.0% at 3 years after diagnosis in patients with synchronous bilateral Wilms tumor and 19.3% in those with metachronous bilateral Wilms tumor. For end stage renal disease due to chronic renal failure stromal predominant histology had a HR of 6.4 relative to mixed (95% CI 3.4, 11.9; p<0.001), intralobar rests had a HR of 5.9 relative to no rests (95% CI 2.0, 17.3; p=0.001), and Wilms tumor diagnosis at less than 24 months had a HR of 1.7 relative to 24 to 48 months and 2.8 relative to greater than 48 months (p=0.003 for trend). CONCLUSIONS: Metachronous bilateral Wilms tumor is associated with high rates of end stage renal disease due to surgery for progressive Wilms tumor. Characteristics associated with a WT1 etiology markedly increased the risk of end stage renal disease due to chronic renal failure despite the low risk in non-WT1 syndromic cases overall.
Authors: V Schumacher; K Schärer; E Wühl; H Altrogge; K E Bonzel; M Guschmann; T J Neuhaus; R M Pollastro; E Kuwertz-Bröking; M Bulla; A M Tondera; P Mundel; U Helmchen; R Waldherr; A Weirich; B Royer-Pokora Journal: Kidney Int Date: 1998-06 Impact factor: 10.612
Authors: J R Horwitz; M L Ritchey; J Moksness; N E Breslow; G R Smith; P R Thomas; G Haase; R C Shamberger; J B Beckwith Journal: J Pediatr Surg Date: 1996-08 Impact factor: 2.545
Authors: C Jeanpierre; E Denamur; I Henry; M O Cabanis; S Luce; A Cécille; J Elion; M Peuchmaur; C Loirat; P Niaudet; M C Gubler; C Junien Journal: Am J Hum Genet Date: 1998-04 Impact factor: 11.025
Authors: Suzanne E Little; Sandra P Hanks; Linda King-Underwood; Chris Jones; Elizabeth A Rapley; Nazneen Rahman; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: Michael K Brawer; Stacy Loeb; Alan W Partin; Jayabalan Nirmal; Michael B Chancellor; J Curtis Nickel; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn Journal: Rev Urol Date: 2011
Authors: Rodrigo B Interiano; Noel Delos Santos; Sujuan Huang; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel M Green; Andrew M Davidoff Journal: Cancer Date: 2015-04-01 Impact factor: 6.860
Authors: Yevgeny Grigoriev; Jane Lange; Susan M Peterson; Janice R Takashima; Michael L Ritchey; Dicken Ko; James H Feusner; Robert C Shamberger; Daniel M Green; Norman E Breslow Journal: Pediatr Nephrol Date: 2012-03-20 Impact factor: 3.714
Authors: Daniel M Green; Mingjuan Wang; Matthew J Krasin; Andrew M Davidoff; DeoKumar Srivastava; Dennis W Jay; Kirsten K Ness; Barry L Shulkin; Sheri L Spunt; Deborah P Jones; Jennifer Q Lanctot; Kyla C Shelton; Rachel C Brennan; Daniel A Mulrooney; Matthew J Ehrhardt; Todd M Gibson; Beth A Kurt; Leslie L Robison; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2020-07-24 Impact factor: 3.167
Authors: Peter F Ehrlich; Yueh-Yun Chi; Murali M Chintagumpala; Fredric A Hoffer; Elizabeth J Perlman; John A Kalapurakal; Brett Tornwall; Anne Warwick; Robert C Shamberger; Geetika Khanna; Thomas E Hamilton; Kenneth W Gow; Arnold C Paulino; Eric J Gratias; Elizabeth A Mullen; James I Geller; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome Journal: Cancer Date: 2020-05-27 Impact factor: 6.860